Dissecting the Transcriptional and Chromatin Accessibility Heterogeneity of Proliferating Cone Precursors in Human Retinoblastoma Tumors by Single Cell Sequencing-Opening Pathways to New Therapeutic Strategies?


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
03 05 2021
Historique:
entrez: 18 5 2021
pubmed: 19 5 2021
medline: 2 10 2021
Statut: ppublish

Résumé

Retinoblastoma (Rb) is a malignant neoplasm arising during retinal development from mutations in the RB1 gene. Loss or inactivation of both copies of RB1 results in initiation of retinoblastoma tumors; however, additional genetic changes are needed for the continued growth and spread of the tumor. Ex vivo research has shown that in humans, retinoblastoma may initiate from RB1-depleted cone precursors. Notwithstanding, it has not been possible to assess the full spectrum of clonal types within the tumor itself in vivo and the molecular changes occurring at the cells of origin, enabling their malignant conversion. To overcome these challenges, we have performed the first single cell (sc) RNA- and ATAC-Seq analyses of primary tumor tissues, enabling us to dissect the transcriptional and chromatin accessibility heterogeneity of proliferating cone precursors in human Rb tumors. Two Rb tumors each characterized by two pathogenic RB1 mutations were dissociated to single cells and subjected to scRNA-Seq and scATAC-Seq using the 10× Genomics platform. In addition, nine human embryonic and fetal retina samples were dissociated to single cells and subjected to scRNA- and ATAC-Seq analyses. The scRNA- and ATAC-Seq data were embedded using Uniform Manifold Approximation and Projection and clustered with Seurat graph-based clustering. Integrated scATAC-Seq analysis of Rb tumors and human embryonic/fetal retina samples was performed to identify Rb cone enriched subclusters. Pseudo time analysis of proliferating cones in the Rb samples was performed with Monocle. Ingenuity Pathway Analysis was used to identify the signaling pathway and upstream regulators in the Rb cone-enriched subclusters. Our single cell analyses revealed the predominant presence of cone precursors at different stages of the cell cycle in the Rb tumors and among those identified the G2/M subset as the cell type of origin. scATAC-Seq analysis identified two Rb enriched cone subclusters, each characterized by activation of different upstream regulators and signaling pathways, enabling proliferating cone precursors to escape cell cycle arrest and/or apoptosis. Our study provides evidence of Rb tumor heterogeneity and defines molecular pathways that can be targeted to define new treatment strategies.

Identifiants

pubmed: 34003213
pii: 2772603
doi: 10.1167/iovs.62.6.18
pmc: PMC8132003
doi:

Substances chimiques

Chromatin 0
RB1 protein, human 0
Retinoblastoma Binding Proteins 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/T004460/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S035826/1
Pays : United Kingdom

Références

Oncogene. 2020 Jan;39(3):503-515
pubmed: 31527667
Semin Cancer Biol. 2022 Feb;79:58-67
pubmed: 32741700
Nature. 2014 Oct 16;514(7522):385-8
pubmed: 25252974
Cell. 2007 Oct 19;131(2):378-90
pubmed: 17956737
Pediatr Hematol Oncol. 2013 Oct;30(7):646-54
pubmed: 23988008
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643228
Asia Pac J Oncol Nurs. 2017 Jul-Sep;4(3):197-204
pubmed: 28695165
Arch Ophthalmol. 1997 Feb;115(2):213-9
pubmed: 9046256
Genes (Basel). 2020 Jan 21;11(2):
pubmed: 31973216
Neuron. 2017 May 3;94(3):550-568.e10
pubmed: 28472656
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cell. 2009 Jun 12;137(6):1018-31
pubmed: 19524506
Nature. 1998 Sep 10;395(6698):124-5
pubmed: 9744267
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4192-9
pubmed: 14507860
Hum Mol Genet. 2008 May 15;17(10):1363-72
pubmed: 18211953
Genes Dev. 1997 May 15;11(10):1242-52
pubmed: 9171369
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33628-33638
pubmed: 33318192
Oncol Rep. 2008 Mar;19(3):825-30
pubmed: 18288422
Clin Transl Med. 2017 Nov 9;6(1):42
pubmed: 29124525
Br J Ophthalmol. 2009 Jan;93(1):38-9
pubmed: 18838414
Cancer Res. 2011 Jun 15;71(12):4205-13
pubmed: 21515735
Trends Cancer. 2020 Jan;6(1):13-19
pubmed: 31952776
Clin Proteomics. 2016 Oct 26;13:29
pubmed: 27799869
Nature. 1992 Sep 24;359(6393):288-94
pubmed: 1406932
Nat Genet. 2017 Oct;49(10):1428-1436
pubmed: 28869592
Nature. 1992 Sep 24;359(6393):295-300
pubmed: 1406933
Pediatr Hematol Oncol. 2005 Sep;22(6):463-81
pubmed: 16169813
Nature. 2012 Jan 11;481(7381):329-34
pubmed: 22237022
Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92
pubmed: 31701148
Cancer Cell. 2011 Aug 16;20(2):260-75
pubmed: 21840489
Arch Ophthalmol. 2006 Sep;124(9):1269-75
pubmed: 16966622
Nature. 2006 Nov 2;444(7115):61-6
pubmed: 17080083
Front Cell Neurosci. 2015 Mar 17;9:86
pubmed: 25852478
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
pubmed: 5279523
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9391-E9400
pubmed: 30213853
Eur Biophys J. 2016 Oct;45(7):621-633
pubmed: 27342111
Nature. 1992 Sep 24;359(6393):328-30
pubmed: 1406937
Biochem Biophys Res Commun. 2008 Oct 10;375(1):1-5
pubmed: 18644346
Trends Mol Med. 2016 Oct;22(10):863-876
pubmed: 27567287
Development. 2013 Feb;140(4):740-50
pubmed: 23318640
Proteomics Clin Appl. 2018 Sep;12(5):e1700101
pubmed: 29742327
Am J Pathol. 2010 Jul;177(1):424-35
pubmed: 20508032
Development. 2019 Jan 29;146(2):
pubmed: 30696714
Cell Rep. 2018 Nov 27;25(9):2510-2523.e4
pubmed: 30485816
J Neurochem. 1985 Dec;45(6):1836-41
pubmed: 2865336
Biochem Mol Biol Int. 1998 Dec;46(5):987-91
pubmed: 9861453
Genes Dev. 2008 Jan 15;22(2):179-93
pubmed: 18198336
Oncogene. 2012 Aug 9;31(32):3721-32
pubmed: 22120712
Cell Rep. 2020 Feb 4;30(5):1644-1659.e4
pubmed: 32023475

Auteurs

Joseph Collin (J)

Biosciences Institute, Newcastle University, Newcastle, United Kingdom.

Rachel Queen (R)

Biosciences Institute, Newcastle University, Newcastle, United Kingdom.

Darin Zerti (D)

Biosciences Institute, Newcastle University, Newcastle, United Kingdom.

David H Steel (DH)

Biosciences Institute, Newcastle University, Newcastle, United Kingdom.

Claire Bowen (C)

Birmingham Women's and Children NHS Foundation Trust, Birmingham, United Kingdom.

Manoj Parulekar (M)

Birmingham Women's and Children NHS Foundation Trust, Birmingham, United Kingdom.

Majlinda Lako (M)

Biosciences Institute, Newcastle University, Newcastle, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH